Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAP-CHF: Ablation and Hemodynamic Monitoring in HFpEF with AF
NCT04160000Phase 4Recruiting
- Sponsor
- Electrophysiology Research Foundation
- Start
- Jul 2020
- Primary completion
- Dec 2024
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial in Atrial fibrillation (AFib) and heart failure with preserved ejection fraction (HFpEF) (4 arms), sponsored by Electrophysiology Research Foundation. Primary endpoint: Time to Composite of Heart failure hospitalizations and/or Cardiovascular mortality at 12 months. Started Jul 2020; status: recruiting.
02
Conditions
Atrial fibrillation (AFib)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT04160000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04160000.